Goldman Sachs
ATHE

Goldman Sachs’s Alterity Therapeutics ATHE Stock Holding History

Goldman Sachs’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-833
Closed -$113K – 7109
2014
Q2 		$113K Sell
833
-4,805
-85% -$548K ﹤0.01% 6505
2014
Q1 		$947K Buy
+5,638
New +$3.11M ﹤0.01% 4725

Other funds holding ATHE

VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
CAM
Columbia Asset Management Ann Arbor, Michigan $575M AUM 29.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Goldman Sachs's ATHE Position: Q4 2014 in Review

Goldman Sachs sold out of Alterity Therapeutics (ATHE) in Q4 2014, closing a stake of 526 shares — an estimated $67K sold.

Goldman Sachs first reported a position in ATHE in Q3 2013 and held it in 5 quarters. The position peaked at $271K in Q4 2013. 24 funds tracked by Wall St. Rank hold ATHE as of Q4 2014.

  • Goldman Sachs reported no remaining Alterity Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Goldman Sachs sold 526 Alterity Therapeutics shares in Q4 2014, an estimated $67K.
  • Goldman Sachs first reported a position in Alterity Therapeutics in Q3 2013 and held it in 5 quarters.
  • Goldman Sachs's Alterity Therapeutics position peaked at $271K in Q4 2013.
  • 24 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q4 2014.

Based on Goldman Sachs's 13F filing for Q4 2014, filed 13 Feb 2015.